Adaptive Biotechnologies officer sale is tax sell-to-cover

Adaptive Biotechnologies Corp Chief Commercial Officer for Immune Medicine, Sharon Benz eno, reported an open-market sale of 63,103 shares of common stock at $13.17 per share.

Accepted by SEC EDGAR 03/13/2026 - 08:55 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief Commercial Officer for Immune Medicine, Sharon Benz eno, reported an open-market sale of 63,103 shares of common stock at $13.17 per share. After the transaction, she directly holds 272,751 shares.

The company’s equity plan required this sale to cover tax withholding on vested restricted stock units, so it was a mandated “sell-to-cover” transaction rather than a discretionary trade.

Insights

Equity compensation and insider-trading analyst

Mandated tax “sell-to-cover” sale, not a discretionary stock disposal.

Chief Commercial Officer Sharon Benz eno sold 63,103 shares of Adaptive Biotechnologies common stock at $13.17 per share. Footnote disclosure states the sale was required to satisfy tax withholding obligations tied to RSU vesting under the company’s equity incentive plans.

Because the transaction was mandated and structured as a “sell to cover,” it carries weak informational content about management’s view of the stock. Benz eno retains 272,751 shares directly after the sale, indicating a continuing, substantial equity position in the company.

Insider Trade Summary

Net Seller: 63,103 shares

Net Sell 1 txn

Insider BENZENO SHARON

Role Chief Commercial Ofc Imm Med

Sold 63,103 shs ($831K)

Type	Security	Shares	Price	Value
Sale	Common Stock	63,103	$13.17	$831K

Holdings After Transaction: Common Stock — 272,751 shares (Direct)

Footnotes (1)

1. F1. This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Adaptive Biotechnologies (ADPT) report for Sharon Benz eno?

Adaptive Biotechnologies reported that Chief Commercial Officer Sharon Benz eno sold 63,103 shares of common stock at $13.17 per share. The Form 4 shows this as an open-market sale linked to tax withholding obligations on vested restricted stock units under the company’s equity incentive plans.

Was the ADPT insider stock sale by Sharon Benz eno a discretionary trade?

No. The filing explains the 63,103-share sale was required to cover tax withholding from RSU vesting. It was a mandated “sell to cover” transaction under Adaptive Biotechnologies’ equity plans, meaning it does not represent a voluntary decision by Sharon Benz eno to reduce her holdings.

How many Adaptive Biotechnologies (ADPT) shares does Sharon Benz eno hold after the sale?

Following the tax-related sale, Sharon Benz eno directly holds 272,751 shares of Adaptive Biotechnologies common stock. This remaining position, disclosed in the Form 4, indicates she continues to have a sizable equity stake in the company after satisfying her RSU tax obligations.

What price was received in the Adaptive Biotechnologies (ADPT) insider sale?

The reported transaction shows 63,103 shares of Adaptive Biotechnologies common stock sold at a price of $13.17 per share. This price is taken directly from the Form 4 and applies to the shares sold to meet RSU-related tax withholding requirements.

Does the ADPT Form 4 indicate any option exercises or derivative transactions?

No derivative transactions are listed in this Form 4 for Adaptive Biotechnologies. The derivativeSummary section is empty, and the transaction data show only a single non-derivative common stock sale tied to tax withholding on vested RSUs, with no option exercises or conversions disclosed.

How should investors interpret this Adaptive Biotechnologies (ADPT) Form 4 filing?

The filing describes a tax-driven “sell-to-cover” sale rather than a discretionary stock sale. Because the 63,103-share transaction was mandated to cover RSU tax obligations and Benz eno still holds 272,751 shares, it is generally viewed as routine compensation-related activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENZENO SHARON

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Ofc Imm Med

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		S(1)		63,103	D	$13.17	272,751	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

	/s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.